Phil Nadeau
Stock Analyst at TD Cowen
(2.78)
# 1,748
Out of 5,182 analysts
26
Total ratings
48%
Success rate
34.73%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRZN Surrozen | Initiates: Buy | n/a | $30.98 | - | 1 | Apr 21, 2026 | |
| BIIB Biogen | Maintains: Buy | $175 → $215 | $183.38 | +17.24% | 7 | Feb 9, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $175 → $200 | $128.12 | +56.10% | 1 | Dec 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $50 → $45 | $40.99 | +9.78% | 1 | Oct 31, 2025 | |
| KURA Kura Oncology | Reiterates: Buy | n/a | $8.83 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $84.18 | -22.78% | 2 | Nov 6, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $53.30 | +125.14% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $430.14 | +16.24% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $42.98 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $16.66 | - | 1 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.96 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.00 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.31 | - | 1 | Jul 16, 2018 |
Surrozen
Apr 21, 2026
Initiates: Buy
Price Target: n/a
Current: $30.98
Upside: -
Biogen
Feb 9, 2026
Maintains: Buy
Price Target: $175 → $215
Current: $183.38
Upside: +17.24%
Neurocrine Biosciences
Dec 5, 2025
Maintains: Buy
Price Target: $175 → $200
Current: $128.12
Upside: +56.10%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $40.99
Upside: +9.78%
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $8.83
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $84.18
Upside: -22.78%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $53.30
Upside: +125.14%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $430.14
Upside: +16.24%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $42.98
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $16.66
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.96
Upside: -
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.00
Upside: -
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $7.31
Upside: -